Aytu BioScience (OTCQX:AYTU) announces that it has entered into agreements with five leading Asian specialty medical distributors to commercialize the Company's MiOXSYS System. MiOXSYS is the company's in vitro diagnostic platform for assessing the level of oxidative stress in semen as an aid in the diagnosis of infertility in men. The MiOXSYS System obtained CE Marking earlier this year.
The Asian commercial network includes Naka International Corporation in Japan, CNC Biotech in Korea, Chun Fo Pharmaceutical in Hong Kong and Macau, and Trivector Biomed and Neoteric Medical Systems in India.
Aytu expects to expand its ex-U.S. distribution channel in line with ramping commercial sales in territories where MiOXSYS is approved while awaiting FDA clearance in the US.
Subscribe for full text news in your inbox